Literature DB >> 21251433

Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment.

Ayelet Eppel Borgida1, Shady Ashamalla, Wigdan Al-Sukhni, Heidi Rothenmund, David Urbach, Malcolm Moore, Michelle Cotterchio, Steven Gallinger.   

Abstract

BACKGROUND: Pancreatic adenocarcinoma (PA) is largely incurable, although recent progress has been made in the safety of surgery for PA and in adjuvant and palliative chemotherapy. The purpose of this study was to describe the management of PA in Ontario, Canada.
METHODS: The Pathology Information Management System (PIMS), which uses electronic pathology reporting (E-path), was used to rapidly identify and recruit patients based on a pathologic diagnosis of PA between 2003 and 2006. Patients were mailed questionnaires for additional data.
RESULTS: The patient participation rate was 26% (351 of 1325). Nonresponders were more likely to be older than 70 years (43% v. 28%, p < 0.001) and to have received treatment in nonacademic centres (53% v. 34%, p < 0.001). Fifty-four percent of responders underwent a potentially curative operation, and most (77%) were 70 years or younger (p = 0.03). Completed resections were documented in 83% of patients who underwent exploratory surgery with curative intent; 17% of patients had unresectable and/or metastatic disease at laparotomy. Of the completed resections, 24% were performed in nonacademic centres with a 32% positive margin rate; 76% were performed in academic centres with a 29% positive margin rate (p = 0.84). Resections with curative intent were less frequently aborted in academic centres (10% v. 33%, p < 0.001). Of the patients who responded to our questionnaire, 43% received chemotherapy and 7% participated in clinical trials.
CONCLUSION: Despite using PIMS and E-path, the response rate for this study was low (< 30%). Nonresponders were older and more commonly treated in nonacademic centres. Patients undergoing surgery in academic centres had higher resection rates. The rate of adjuvant and palliative chemotherapy was stage-dependent and low.

Entities:  

Mesh:

Year:  2011        PMID: 21251433      PMCID: PMC3038358          DOI: 10.1503/cjs.026409

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  17 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

2.  Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer.

Authors:  Timothy M Pawlik; Eddie K Abdalla; Carlton C Barnett; Syed A Ahmad; Karen R Cleary; Jean-Nicolas Vauthey; Jeffrey E Lee; Douglas B Evans; Peter W T Pisters
Journal:  Arch Surg       Date:  2005-06

Review 3.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

Review 4.  Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials.

Authors:  Gabriel Y Lai; Tiffany L Gary; Jon Tilburt; Shari Bolen; Charles Baffi; Renee F Wilson; Mollie W Howerton; M Chris Gibbons; Teerath Peter Tanpitukpongse; Neil R Powe; Eric B Bass; Jean G Ford
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

5.  Analysis of treatment practices for elderly cancer patients in Ontario, Canada.

Authors:  Carol Townsley; Gregory R Pond; Brenda Peloza; Joanne Kok; Kendra Naidoo; Darlene Dale; Carole Herbert; Eric Holowaty; Sharon Straus; Lillian L Siu
Journal:  J Clin Oncol       Date:  2005-06-01       Impact factor: 44.544

Review 6.  Adjuvant treatment strategies for pancreatic cancer.

Authors:  Erika A Newman; Diane M Simeone; Michael W Mulholland
Journal:  J Gastrointest Surg       Date:  2006-06       Impact factor: 3.452

7.  National failure to operate on early stage pancreatic cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

8.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

9.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

10.  Surgeon volume and operative mortality in the United States.

Authors:  John D Birkmeyer; Therese A Stukel; Andrea E Siewers; Philip P Goodney; David E Wennberg; F Lee Lucas
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

View more
  7 in total

1.  Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec.

Authors:  A L Smith; C Bascuñana; A Hall; A Salman; A Z Andrei; A Volenik; H Rothenmund; D Ferland; D Lamoussenery; A S Kamath; R Amre; D Caglar; Z H Gao; D G Haegert; Y Kanber; R P Michel; G Omeroglu-Altinel; J Asselah; N Bouganim; P Kavan; G Arena; J Barkun; P Chaudhury; S Gallinger; W D Foulkes; A Omeroglu; P Metrakos; G Zogopoulos
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.

Authors:  Yun Feng; Hongliang Liu; Bensong Duan; Zhensheng Liu; James Abbruzzese; Kyle M Walsh; Xuefeng Zhang; Qingyi Wei
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

3.  Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.

Authors:  Bensong Duan; Jiangfeng Hu; Hongliang Liu; Yanru Wang; Hongyu Li; Shun Liu; Jichun Xie; Kouros Owzar; James Abbruzzese; Herbert Hurwitz; Hengjun Gao; Qingyi Wei
Journal:  Int J Cancer       Date:  2017-12-04       Impact factor: 7.396

4.  Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

Authors:  Robert C Grant; Iris Selander; Ashton A Connor; Shamini Selvarajah; Ayelet Borgida; Laurent Briollais; Gloria M Petersen; Jordan Lerner-Ellis; Spring Holter; Steven Gallinger
Journal:  Gastroenterology       Date:  2014-12-02       Impact factor: 22.682

5.  Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer.

Authors:  Alyssa L Smith; Najmeh Alirezaie; Ashton Connor; Michelle Chan-Seng-Yue; Robert Grant; Iris Selander; Claire Bascuñana; Ayelet Borgida; Anita Hall; Thomas Whelan; Spring Holter; Treasa McPherson; Sean Cleary; Gloria M Petersen; Atilla Omeroglu; Emmanouil Saloustros; John McPherson; Lincoln D Stein; William D Foulkes; Jacek Majewski; Steven Gallinger; George Zogopoulos
Journal:  Cancer Lett       Date:  2015-11-03       Impact factor: 8.679

6.  A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.

Authors:  Cavin Wong; Fei Chen; Najmeh Alirezaie; Yifan Wang; Adeline Cuggia; Ayelet Borgida; Spring Holter; Tatiana Lenko; Celine Domecq; Gloria M Petersen; Sapna Syngal; Randall Brand; Anil K Rustgi; Michele L Cote; Elena Stoffel; Sara H Olson; Nicholas J Roberts; Mohammad R Akbari; Jacek Majewski; Alison P Klein; Celia M T Greenwood; Steven Gallinger; George Zogopoulos
Journal:  PLoS Genet       Date:  2019-08-30       Impact factor: 5.917

7.  Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk.

Authors:  Lingling Zhao; Hongliang Liu; Sheng Luo; Patricia G Moorman; Kyle M Walsh; Wei Li; Qingyi Wei
Journal:  Cancer Med       Date:  2020-11-16       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.